GENIX PHARMACEUTICALS CORPORATION

(FORMERLY: ALTA NATURAL HERBS & SUPPLEMENTS LTD.)

Financial Statements

For the three months ended January 31, 2021 and 2020

(Expressed in Canadian Dollars)

The accompanying notes are an integral part of these financial statements.

NOTICE OF NO AUDITOR REVIEW OF CONDENSED INTERIM FINANCIAL STATEMENTS

In accordance with National Instrument 51-102, Part 4, subsection 4.3(3)(a), if an auditor has not performed a review of the condensed interim consolidated financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed interim financial statements of the Company have been prepared by and are the responsibility of the Company’s management.

The Company's independent auditor has not performed a review of these financial statements in accordance with the standards established by the Chartered Professional Accountants of Canada for a review of condensed interim financial statements by an entity's auditor.

GENIX PHARMACEUTICALS CORPORATION
Condensed Statements of Financial Position
(Expressed in Canadian dollars)

	Note	January 31, 2021	October 31, 2020
Assets			
Current assets			
Cash		$ 532,034	$ 696,607
Receivables		9,979	7,907
Prepaid expense		19,185	11,247
		561,198	715,761
Non-current assets			
Intellectual property	4	4,499,264	4,623,889
Website	5	7,344	7,544
		$ 5,067,806	**$ 5,347,194**
Liabilities and Equity (Deficiency)			
Current liabilities			
Trade and other payables	6	$ 61,517	$ 137,192
Loans from shareholders	7	15,183	15,183
Obligation - current portion	4	197,500	197,500
		274,200	349,875
Non-current liabilities			
Obligation - long term	4	140,000	140,000
Total liabilities		414,200	489,875
Equity (Deficiency)			
Share capital	9	9,700,762	9,700,762
Warrants reserve	9	12,730	12,730
Share options reserve	9	341,966	152,442
Accumulated deficit		(5,401,852)	(5,008,615)
		4,653,606	4,857,319
		$ 5,067,806	**$ 5,347,194**

Corporate Information and Nature of Operations (Note 1)
Subsequent Event (Note 13)

Approved by the Board of Directors on March 26, 2021

Sina Pirooz — Director

Kevin Bottomley — Director

GENIX PHARMACEUTICALS CORPORATION
Condensed Statements of Comprehensive Income (Loss)
(Expressed in Canadian dollars)

		Three months ended January 31,	
	Note	**2021**	2020
Sales		$ **-**	$ -
Cost of goods sold		**-**	-
Gross profit (Loss)		**-**	-
Operating expenses			
Amortization	4	$ **124,825**	$ -
Bank charge and interest		**150**	564
Consulting	8	**46,706**	-
Office and msicellaneous		**8,685**	-
Professional fees	8	**19,000**	31,455
Regulatory		**4,710**	5,879
Rent		**531**	-
Stock based compensation	9	**189,524**	-
		$ **394,131**	$ 37,898
Income (loss) before other items		**(394,131)**	(37,898)
Other items			
Foreign exchange gain (loss)		**(3)**	85
Interest income		**897**	41
		894	126
Comprehensive and net income (loss) for the year		$ **(393,237)**	$ (37,772)
Basic and diluted income (loss) per share			
Comprehensive and net income (loss for the year)		$ **(0.01)**	$ (0.00)
Weighted average common shares outstanding		**59,224,131**	37,514,237

GENIX PHARMACEUTICALS CORPORATION
Condensed Statements of Cash Flows
(Expressed in Canadian dollars)

	Three months ended January 31,	
	2021	2020
Operating activities		
Net income (loss) for the period	$ **(393,237)**	$ (37,772)
Items not affecting cash and cash equivalents		
Amortization	**124,825**	-
Share based payments	**189,524**	-
Interest on loan from shareholder		523
Changes in non-cash working capital		
Receivables	**(2,072)**	-
Prepaids	**(7,938)**	5,000
Accounts payable and accrued liabilities	**(75,675)**	(11,865)
Sales tax	**-**	(1,205)
Total cash outflows from operating activities	$ **(164,573)**	$ (45,319)
Financing activities		
Loans from shareholders	$ **-**	$ 20,000
Total cash inflows from financing activities	$ **-**	$ 20,000
Net change in cash	$ **(164,573)**	$ (25,319)
Cash, beginning of period	**696,607**	31,347
Cash, end of period	$ **532,034**	$ 6,028

GENIX PHARMACEUTICALS CORPORATION
Condensed Statement of Changes in Equity (Deficiency)
(Expressed in Canadian dollars)

	Note	Number of shares	Share capital	Warrants reserve	Share options reserve	Accumulated foreign currency translation differences	Accumulated deficit	Total
Balance, October 31, 2019		37,514,237	$ 4,192,298	$ -	$ 55,519	$ -	$ (4,289,952)	$ (42,135)
Comprehensive loss for the period		-	-	-	-	-	(37,772)	(37,772)
Balance, January 31, 2020		37,514,237	4,192,298	-	55,519	-	(4,327,724)	(79,907)
Shares issued, private placement	9	6,709,894	1,006,484		-	-	-	1,006,484
Share issuance costs, private placement	9	-	(33,020)	12,730	-	-	-	(20,290)
Shares issued for intellectual property	4	15,000,000	4,535,000	-	-	-	-	4,535,000
Share based payments	9	-	-	-	96,923	-	-	96,923
Comprehensive loss for the period		-	-	-	-	-	(680,891)	(680,891)
Balance, October 31, 2020		59,224,131	9,700,762	12,730	152,442	-	(5,008,615)	4,857,319
Comprehensive loss for the year		-	-	-	-	-	(393,237)	(393,237)
Share based payments		-	-	-	189,524	-	-	189,524
Balance, January 31, 2021		59,224,131	$ 9,700,762	$ 12,730	$ 341,966	$ -	$ (5,401,852)	$ 4,653,606

1. CORPORATE INFORMATION AND NATURE OF OPERATIONS

Genix Pharmaceuticals Corporation (formerly Alta Natural Herbs & Supplements Ltd.) (the "Company" or "Genix") was incorporated under the Alberta Business Corporations Act on July 12, 1993 and is currently a publicly traded company listed on the TSX Venture Exchange under the symbol "GENX". The Company is a formulator, manufacturer, licensor and marketer of life sciences related products with a focus on nutraceuticals and pharmaceuticals.

The Company's registered office, principal address and registered and records office is 10022 – 102 Avenue, Grand Prairie, Alberta, T8V 0Z7.

The financial statements were authorized by the Board of Directors on March 26, 2021.

These financial statements have been prepared in accordance with International Financial Reporting Standards with the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business.

These financial statements have been prepared by management on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The continuing operations of the Company are dependent upon its ability to continue to raise adequate financing and to commence profitable operations in the future. In the event that cash flow from operations, if any, together with the proceeds from any future financings are insufficient to meet the Company's current operating expenses, the Company will be required to re-evaluate its planned expenditures and allocate its total resources in such a manner as the Board of Directors and management deems to be in the Company's best interest. This may result in a substantial reduction of the scope of existing and planned operations.

These financial statements do not reflect any adjustments, which could be material, to the carrying values of assets and liabilities, which may be required should the Company be unable to continue as a going concern.

The Company's continuing operations are dependent upon its ability to raise capital and generate cash flow. At January 31, 2021, the Company had a positive working capital of $286,998 (October 31, 2020 – $365,886), had not generated sufficient revenues to cover expenses and had an accumulated deficit of $5,401,852 (October 31, 2020 - $5,008,615). The continuation of the Company as a going concern is dependent on generating future cash flows and obtaining necessary financing to fund ongoing operations. In March 2020, the World Health Organization recognized the outbreak of COVID-19 as a global pandemic. The COVID-19 pandemic and government actions implemented to contain the further spread of COVID-19 have severely restricted economic activity around the world. These factors indicate the existence of material uncertainties which may cast significant doubt upon the Company's ability to continue as a going concern. The Company believes that it has sufficient working capital to maintain operations for the next 12 months.

2. BASIS OF PRESENTATION

Statement of compliance

The financial statements of the Company have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC").

Basis of presentation

The financial statements have been prepared on a historical cost basis except for certain financial assets measured at fair value. All dollar amounts presented are in Canadian dollars unless otherwise specified.

Key Sources of Estimation Uncertainty

Critical judgments

Areas requiring a significant degree of judgment that relate to the ability to continue as a going concern are discussed in Note 1.

Share-based payments

Estimating the fair value for granted stock options and compensatory warrants requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. The estimate also requires determining the most appropriate model including the expected life of the option or warrant, volatility, dividend yield, and rate of forfeitures and making assumptions about them.

Carrying values of intangible assets

The Company assesses the carrying value of its intangible assets annually or more frequently if warranted by a change in circumstances. If it is determined that carrying values of assets cannot be recovered, the unrecoverable amounts are charged against current earnings. Recoverability is dependent upon assumptions and judgments regarding market conditions, cost of operations and sustaining capital requirements. Other assumptions used in the calculation of recoverable amounts are discount rates and future cash flows. A material change in the assumptions may significantly impact the potential impairment of these assets.

Impairment

Assets are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their recoverable amounts and also at each reporting period. The assessment of the carrying amount often requires estimates and assumptions such as discount rates, future capital requirements and future operating performance.

Useful lives of intangible assets

Estimates of the useful lives of intangible assets are based on the period over which the assets are expected to be available for use. The estimated useful lives are reviewed annually and are updated if expectations differ from previous estimates due to technical or commercial obsolescence, and legal or other limits on the use of the relevant assets. In addition, the estimation of the useful lives of the relevant assets may be based on internal technical evaluation and experience with similar assets. It is possible, however, that future results of operations could be materially affected by changes in the estimates brought about by changes in the factors mentioned above. The amounts and timing of recorded expenses for any period would be affected by changes in these factors and circumstances.

Recovery of deferred tax assets

Judgment is required in determining whether deferred tax assets are recognized on the statement of financial position. Deferred tax assets, including those arising from un-utilized tax losses require management to assess the likelihood that the Company will generate taxable earnings in future years, to utilize recognized deferred tax assets. Estimates of future taxable income are based on forecasted cash flows from operations and the application of existing tax laws in each jurisdiction. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted. Additionally, future changes in tax laws in the jurisdictions in which the Company operates could limit the ability of the Company to obtain tax deductions in future years.

(Expressed in Canadian dollars)

3. SIGNIFICANT ACCOUNTING POLICIES

These condensed interim financial statements have been prepared on the basis of accounting policies and methods of computation consistent with those applied in the Company's annual financial statements for the year ended October 31, 2020.

Upcoming standards

There are no upcoming standards that will have a material impact on the Company's financial statements.

4. Intellectual Property

		Ophthalmic Drugs		Sucanon		Renochlor		Flu-X		Total
Cost:										
Balance, October 31, 2019	$	-	$	-	$	-	$	-	$	-
Acquisitions		4,535,000		100,000		250,000		100,000		4,985,000
Balance, October 31, 2020 & January 31, 2021	$	4,535,000	$	100,000	$	250,000	$	100,000	$	4,985,000
Accumulated amortization:										
Balance, October 31, 2018 & 2019		-		-		-		-		-
Amortization during the year		326,768		8,082		20,206		6,055		361,111
Balance, October 31, 2020		326,768		8,082		20,206		6,055		361,111
Amortization during the period		113,375		2,500		6,250		2,500		124,625
Balance, January 31, 2021		440,143		10,582		26,456		8,555		485,736
Net book value:										
As at October 31, 2020		4,208,232		91,918		229,794		93,945		4,623,889
As at January 31, 2021	$	4,094,857	$	89,418	$	223,544	$	91,445	$	4,499,264

<u>Ophthalmic Drugs</u>
On February 14, 2020, the Company completed the acquisition of 30 World Health Organization approved ophthalmic drugs and product dossiers in exchange for 15,000,000 common shares. These shares were issued at a deemed price of $0.30 per share for a total of $4,535,000 based on the fair value of the asset at the time of acquisition.

<u>Sucanon® and Renochlor®.</u>
On January 10, 2020 the Company entered into an Acquisition Agreement with Canagen Pharmaceuticals Inc. ("Canagen"), to purchase sole and exclusive distribution, sales and marketing rights and interest for Canada, (excluding intellectual property rights) for an initial term of ten years to two nutraceutical products under the brand names SUCANON® and RENOCHLOR®.

SUCANON® is a nutraceutical for managing and treating diabetes, and RENOCHLOR® is a patented nutraceutical for the prevention and treatment of chronic kidney disease and end stage renal disease.

Genix has agreed to pay Canagen $100,000 for the SUCANON® rights and $250,000 for the RENOCHLOR® rights, for a total of $350,000 to be paid in tranches as follows:

Sucanon

		Amount	Due Date	Status
Principal payment	$	25,000	July 22, 2020	Paid
2nd payment	$	35,000	July 22, 2021	Outstanding
3rd payment	$	40,000	July 22, 2022	Outstanding
Total purchase price	**$**	**100,000**		

(Expressed in Canadian dollars)

4. Intellectual Property (continued…)

Renochlor

		Amount	Due Date	Status
Principal payment	$	62,500	July 22, 2020	Paid
2nd payment	$	87,500	July 22, 2021	Outstanding
3rd payment	$	100,000	July 22, 2022	Outstanding
Total purchase price	**$**	**250,000**		

Both the second and third payments due for both SUCANON and RENOCLOR were extended to July 22, 2021 and July 22, 2022 respectively as agreed to by both parties.

If Genix fails to make the 2nd payment, it has agreed to pay Canagen interest in the amount equal to 12% of the outstanding amount from the second anniversary of the Closing Date, plus a penalty in the amount of 1.5%; and

If Genix fails to make the 2nd or 3rd payments of the Purchase Price for a period of longer than three (3) months from the due dates, all rights, including all Natural Product Numbers ("NPNs") issued to Genix by Health Canada or granted to Genix by Canagen shall be immediately transferred and assigned to Canagen. Sucanon® already has a Health Canada issued NPN and can be marketed and sold by the Company immediately, while Renochlor will require Genix to apply for an NPN.

Flu-X
On March 24, 2020, the Company entered into an agreement, with Canagen to purchase the sole and exclusive global distribution, sales and marketing rights and interest for Flu-X®, a novel and proprietary, anti-viral, anti-flu and common colds coronavirus oral and spray herbal product. Genix acquired the Global Rights for a term of ten years, extendable by mutual agreement, by making cash payments to Canagen totaling $100,000, comprising $25,000 paid within four months of closing, and $75,000 within the first anniversary thereafter. Canagen has been paid the first installment of $25,000. The second installment of $75,000 is due on September 21, 2021.

The remaining payment obligations for Sucanon, Renochlor and Flu-X are summarized below:

		Sucanon		Renochlor		Flu-X		Total
Current portion (due in less than 12 months)	$	35,000	$	87,500	$	75,000	$	197,500
Long term portion		40,000		100,000		-		140,000
	$	**75,000**	**$**	**187,500**	**$**	**75,000**	**$**	**337,500**

5. Website

		Website
Cost:		
Balance, October 31, 2018 & 2019	$	-
Additions for the year		8,000
Balance, October 31, 2020 and January 31, 2021	$	8,000
Accumulaizted amortization:		
Balance, October 31, 2018 & 2019	$	-
Amortization during the year		456
Balance, October 31, 2020		456
Amortization during the period		200
Balance, January 31, 2021	$	656
Net book value:		
As at October 31, 2020	$	7,544
As at January 31, 2021	$	7,344

(Expressed in Canadian dollars)

6. Accounts Payable and Accrued Liabilities

The Company's accounts payable and accrued liabilities are as follows:

		January 31, 2021		October 31, 2020
Trade payables	$	30,517	$	116,192
Accrued liabilities		31,000		21,000
	$	61,517	$	137,192

7. Loan from Shareholder

		January 31, 2021		October 31, 2020
Shareholder loans	$	15,183	$	15,183
	$	15,183	$	15,183

The loan from one shareholder carried no interest. There was no collateral pledged against this loan.

8. Related Party Transactions

During the three months ended January 31, 2021, the Company entered into the following transactions with related parties, not disclosed elsewhere in these consolidated financial statements:

- Paid or incurred professional fees of $nil (2020 - $2,380) to a company controlled by an officer of the Company.
- Paid or incurred consulting fees of $15,000 (2020 - $nil) to a company controlled by a director of the Company.
- Paid or incurred consulting fees of $1,500 (2020 - $nil) to an officer of the Company.
- Paid or incurred in consulting and other various expenses of $4,500 (2020 - $Nil) to a company controlled by an officer of the Company. As at January 31, 2021, $1,575 (2020 - $Nil) was included in trade and other payables for consulting fees.
- Stock based compensation of $92,228 (2020 - $Nil) was incurred to directors of the Company.

All related party amounts were incurred in the normal course of operations, bear no interest and have no fixed terms of repayment.

9. Share Capital and Reserves

Authorized Share Capital - Unlimited common shares without par value

Issued Share Capital

	Shares		Share capital - gross		Share issue costs		Share capital - net
Balance, October 31, 2019	37,514,237	$	4,204,215	$	11,917	$	4,192,298
Issued for intellectual property	15,000,000		4,535,000		-		4,535,000
Private placement	6,709,894		1,006,484		33,020		973,464
Balance, October 31, 2020 and January 31, 2021	59,224,131	$	9,745,699	$	44,937	$	9,700,762

(Expressed in Canadian dollars)

9. Share Capital and Reserves (continued…)

On July 17, 2020 and August 6, 2020, the Company closed two tranches of a non-brokered private placement of 6,709,894 units (the "Units") at a price of $0.15 per unit for aggregate gross proceeds of $1,006,484. Each Unit consists of one common share and one-half of one common share purchase warrant (each full warrant, a "Warrant"). Each Warrant entitles the holder to acquire one common share of the Company at an exercise price of $0.30 for a period of 24 months following the closing. The fair value attributable to these share purchase warrants was $nil. The Company paid the agents a cash commission of $13,650 and issued 91,000 broker warrants (valued at $12,730). Each broker warrant entitles the holder to purchase one common share of the Company at a price of $0.30 for a period of 24 months following closing. In addition, the Company also incurred share issuance costs of $6,640.

Warrants

A summary of the warrant activities is as follows:

	Number of warrants		Weighted average exercise price
Balance,October 31, 2019	-	$	-
Issued	3,445,945		0.30
Balance, October 31, 2020 and January 31, 2021	3,445,945	$	0.30

The following share purchase warrants were outstanding as at January 31, 2021:

Expiry date	Number of warrants	Exercise price ($)	Remaining contractual life (years)
July 24, 2022	2,182,112	0.30	1.48
August 13, 2022	1,263,833	0.30	1.53
	3,445,945	**0.30**	**1.50**

The weighted average life of warrants outstanding as at January 31, 2021 is 1.50 years.

Stock Options

The Company has a fixed stock-based compensation plan (the "Plan") providing for the grant of stock options to purchase a maximum of 10% of the issued and outstanding common shares outstanding.

During the three months ended January 31, 2021:

a. In December 2020, the Company granted 550,000 stock options exercisable at $0.30 per share to officers and consultants of the Company. The fair value attributable to these stock options was $77,359 using the Black Scholes option pricing model of which $77,359 was expensed during the period.

During the year ended October 31, 2020:

a. In August 2020, the Company granted 1,400,000 stock options exercisable at $0.30 per share to officers, directors and consultants of the Company. The fair value attributable to these stock options was $117,593 using the Black Scholes option pricing model of which $88,216 was expensed during the year.

b. In September 2020, the Company granted 300,000 stock options exercisable at $0.30 per share to a director of the Company. The fair value attributable to these stock options was $20,847 using the Black Scholes option pricing model of which $8,707 was expensed during the year.

(Expressed in Canadian dollars)

9. Share Capital and Reserves (continued…)

Stock Options (continued…)

The fair value of each option granted is estimated at the time of the grant using the Black-Scholes option pricing model with assumptions for grants as follows:

	Three months ended January 31,	
	2021	**2020**
Risk-free interest rate	0.45%	n/a
Expected life (years)	5.0	n/a
Annualized volatility	147%	n/a
Dividend rate	-	n/a
Grant date fair value	$0.16	n/a

A summary of the stock options activities is as follows:

	Number of options		Weighted average exercise price
Balance, October 31, 2019	-	$	-
Granted	1,700,000		0.30
Balance, October 31, 2020	1,700,000		0.30
Granted	550,000		0.22
Balance, January 31, 2021	**2,250,000**	$	**0.28**

The following table summarizes information about the options outstanding and exercisable at January 31, 2021:

Expiry date	Options outstanding	Options exercisable	Exercise price	Remaining contractual life (years)
August 5, 2025	1,400,000	700,000	0.30	4.36
September 18, 2025	300,000	-	0.30	4.48
December 14, 2025	550,000	550,000	0.30	4.73
	2,250,000	**1,250,000**		

The weighted average life of stock options outstanding at January 31, 2021 is 4.47 years.

Loss per share

The effect of dilutive securities including options and warrants has not been shown as the effect of all such securities is anti-dilutive.

10. Segmented Information

Operating segment:
The Company operated in one operating segment consisting of nutraceutical and pharmaceutical products.

Geographic segments:
The Company operated only in Canada for the three months ended January 31, 2021 and 2020.

11. Financial Instruments and Risk Management

The fair value of the Company's receivables, prepaid deposit, and payables approximate carrying value, due to their short-term nature. The Company's cash is measured at fair value under the fair value hierarchy based on level one quoted prices in active markets for identical assets or liabilities.

The Company's financial instruments are exposed to certain financial risks, including, credit risk, liquidity risk, interest rate risk and price risk, and currency risk.

Credit

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations.

The Company is exposed to credit risk on its cash and receivables. The Company limits its exposure to credit risk by holding its cash in large Canadian financial institutions. The Company does not have any asset-backed commercial paper. The Company performs ongoing credit evaluations of its trade receivables but does not require collateral. The Company establishes an allowance for doubtful accounts based on the credit risk applicable to particular customers and historical data. The Company maintains cash deposits with Schedule A financial institutions, which from time to time may exceed federally insured limits. The Company has not experienced any significant credit losses and believes it is not exposed to any significant credit risk.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

The Company manages liquidity risk through its capital management as outlined in Note 12. The Company's ability to continue as a going concern is dependent on management's ability to raise required funding through future equity issuances and through short-term borrowing. The Company manages its liquidity risk by forecasting cash flows from operations and anticipating any investing and financing activities. Management and the Board of Directors are actively involved in the review, planning and approval of significant expenditures and commitments. As at January 31, 2021, management believes that the Company has sufficient funds to support ongoing operations and meet its liabilities as they fall due.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates.

Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company does not hold any financial liabilities with variable interest rates. The Company does maintain bank accounts which earn interest at variable rates but it does not believe it is currently subject to any significant interest rate risk, as these variable interest rates are minimal.

Price risk

Price risk is the risk associated with equity prices. The Company closely monitors equity prices to determine the appropriate course of action to be taken by the Company.

Foreign exchange risk

The Company's functional and reporting currency is the Canadian dollar; and the functional currency of its discontinued operations was the U.S. dollar. The Company's transactions are predominantly in Canadian dollars, while the transactions of its discontinued operations were predominantly in U.S. dollars. As a result, the Company's exposure to foreign currency risk is minimal.

12. Capital Disclosure and Management

The Company's capital management policy is to maintain a strong, but flexible capital structure that optimizes the cost of capital, creditor and market confidence while sustaining the future development of the business.

The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions. The Company's capital structure includes shareholders' equity of $4,653,606 (October 31, 2020 - $4,857,319). In order to maintain or adjust the capital structure, the Company may from time to time issue shares, seek additional debt financing and adjust its capital spending to manage current and projected debt levels. The Company is not subject to externally imposed capital requirements other than as noted above. There were no changes to the Company's approach to capital management during the three months ended January 31, 2021.

13. Subsequent Event

a) On March 22, 2021, the Company issued 3,650,000 stock options with an exercise price of $0.30 to officers, directors and consultants of the Company. The stock options have a term of 5 years.